The Readout Loud 278: Merger Mondays, Ozempic panic, & CRISPR'd pigs
Oct 12, 2023
The podcast discusses Bristol Myers Squibb's acquisition of Mirati Therapeutics, the rejection of a treatment by Al Nylon, the impact of GLP-1 drugs on the Nash treatment market, and advancements in genetic engineering using CRISPR technology in animals.
Chapters
Transcript
Episode notes
1 2 3 4 5
Introduction
00:00 • 2min
M&A Deal Between Bristol Myers-Squib and Marathi Therapeutics
01:58 • 9min
Rejection of Treatment by Al Nylon and Its Impact
10:55 • 5min
The Impact of GLP-1 Drugs on Nash Treatment Market
16:04 • 9min
Advancements in Genetic Engineering and CRISPR Technology in Animals
25:14 • 8min